ABCB1 polymorphism and acenocoumarol safety in patients with valvular atrial fibrillation

BACKGROUND: Oral anticoagulant drugs (AD) are commonly used to treat patients with thromboembolic diseases. The ADs have narrow therapeutic index and wide pharmacokinetic and pharmacodynamic interindividual variability. Some genetic variations could infl uence interindividual variability in response to AD. Acenocoumarol (AC) is a coumarin, vitamin K derivate with antagonistic activity, used as anticoagulant therapy mainly in Central Europe and Latin America. P – glycoprotein (PGP), a transporter encoded by the ABCB1 gene, plays a major role in the drug disposition [1]. PGP is expressed in normal tissues, where it performs a defensive role against potentially toxic substances in intestinal cells and endothelial cells of the brain capillary endothelium. ABCB1 – is highly polymorphic, C3435T polymorphism in exon 26 has been associated with the expression of PGP [2]. There is some evidence that PGP could infl uence coumarin sensitivity. OBJECTIVE: To assess effects of the ABCB1 pilymorphisms on safety profi le and dosing regimen of acenocoumarol in the patients with valvular atrial fi brillation. METHODS: 50 patients (34 male and 16 female), 40–70 years of age were included. All patients received acenocoumarol at doses of 1–6 mg daily with a target international normalized ratio (INR) of 2.0 to 3.0. Genotyping for polymorphism marker C3435T of ABCB1 gen was performed using PCR and RFLP (restriction fragment length polymorphisms) techniques. Statistics were performed by Fishers exact tests. All enrolled patients provided written informed consent. RESULTS: Genotype CC was found in 10 patients (20%), genotype CT in 25 patients (50%) and genotype TT in 15 patients (30%). In the CC group (n = 10) bleeding was found in 1 patient (2%). There were 19 patients (38%) with bleedings in combined group of CT and TT genotype (p = 0.0366). We compared the average doses of acenocoumarol in groups identifi ed according to their genotypes: CC (3.45 mg/day), CT (2.64 mg/day), TT (3.07 mg/day) and found no signifi cant differences. CONCLUSIONS: ABCB1 CT and TT genotypes were found to be signifi cantly associated with higher risk of bleeding. There was no infl uence of ABCB1 polymorphisms on dosing regimens of acenocoumarol. Confl ict of interest statement: The authors report no confl icts of interest.